Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 15;9:2323. doi: 10.3389/fimmu.2018.02323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Kwun, Park, Yi, Farris, Kirk and Knechtle.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Pre-emptive anti-LFA-1 mAb treatment reduced post-transplant DSA and allo-specific B cells in alemtuzumab treated hCD52Tg cardiac allograft recipients. (A) Dosing scheme and experimental design. (B) Graft survival of human CD52Tg mice received B6 cardiac allografts. Alemtuzumab treatment (IP, 10 μg per dose at POD −2, −1, 2, 4,) with or without anti-LFA-1 mAb (KBA-1; 200 μg per dose at POD 0, 2, 4, 6) significantly prolonged graft survival (MST >100 d) vs. untreated (MST = 9 d). (C) Donor-specific antibody measured by T cell flow crossmatch was significantly decreased in anti-LFA-1 treatment in Alemtuzumab induced CAMR model. (D) Allo-specific B cells visualized by MHC (H-2K^b/D^b) tetramer were significantly reduced with anti-LFA-1 mAb treatment from the spleen at POD100.